ALX Oncology Holdings Inc. announced the presentation of preclinical data and the ongoing Phase 1 clinical trial design for its novel antibody-drug conjugate $(ADC)$ candidate, ALX2004, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The Phase 1 trial is a first-in-human, open-label, multicenter study evaluating the safety, tolerability, and preliminary efficacy of ALX2004 in patients with advanced or metastatic solid tumors known to express EGFR. The company reported that preclinical findings have demonstrated potent anti-tumor activity and a favorable toxicity profile. Initial safety data from the ongoing Phase 1 trial are anticipated in the first half of 2026. The results and trial details were presented in poster sessions at the conference, which is taking place from October 22 to 26, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9551106-en) on October 23, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.